<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Dermatol</journal-id><journal-id journal-id-type="publisher-id">AD</journal-id><journal-title-group><journal-title>Annals of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">1013-9087</issn><issn pub-type="epub">2005-3894</issn><publisher><publisher-name>Korean Dermatological Association; The Korean Society for Investigative Dermatology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27746641</article-id><article-id pub-id-type="pmc">5064191</article-id><article-id pub-id-type="doi">10.5021/ad.2016.28.5.607</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prospective Comparison of Dual Wavelength Long-Pulsed 755-nm Alexandrite/1,064-nm Neodymium:Yttrium-Aluminum-Garnet Laser versus 585-nm Pulsed Dye Laser Treatment for Rosacea</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Seo</surname><given-names>Hyun-Min</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jung-In</given-names></name><xref ref-type="aff" rid="A2">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Han-Saem</given-names></name><xref ref-type="aff" rid="A2">1</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Young-Jun</given-names></name><xref ref-type="aff" rid="A2">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Won-Serk</given-names></name><xref ref-type="aff" rid="A2">1</xref></contrib></contrib-group><aff id="A1">Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</aff><aff id="A2"><label>1</label>Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff><author-notes><corresp>
Corresponding author: Won-Serk Kim, Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea. Tel: 82-2-2001-2411, Fax: 82-2-2001-2236, <email>susini@naver.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>9</month><year>2016</year></pub-date><volume>28</volume><issue>5</issue><fpage>607</fpage><lpage>614</lpage><history><date date-type="received"><day>11</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>13</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 The Korean Dermatological Association and The Korean Society for Investigative Dermatology</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Rosacea treatments including oral/topical medications and laser therapy are numerous but unsatisfactory.</p></sec><sec><title>Objective</title><p>To compare the effectiveness of the dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium: yttrium-aluminum-garnet laser (LPAN) with that of 585-nm pulsed dye laser (PDL) for rosacea.</p></sec><sec><title>Methods</title><p>This was a randomized, single-blinded, comparative study. Full face received four consecutive monthly treatments with LPAN or PDL, followed-up for 6 months after the last treatment. Erythema index was measured by spectrophotometer, and digital photographs were evaluated by consultant dermatologists for physician's global assessment. Subjective satisfaction surveys and adverse effects were recorded.</p></sec><sec><title>Results</title><p>Forty-nine subjects with rosacea enrolled and 12 dropped out. There were no significant differences between LPAN and PDL in the mean reduction of the erythema index (<italic>p</italic>=0.812; 3.6% vs. 2.8%), improvement of physician's global assessment (<italic>p</italic>=1.000; 88.9% vs. 89.5%), and subject-rated treatment satisfaction (<italic>p</italic>=0.842; 77.8% vs. 84.2%). PDL showed more adverse effects including vesicles than LPAN (<italic>p</italic>=0.046; 26.3% vs. 0.0%). No other serious or permanent adverse events were observed in both treatments.</p></sec><sec><title>Conclusion</title><p>Both LPAN and PDL may be effective and safe treatments for rosacea.</p></sec></abstract><kwd-group><kwd>Alexandrite</kwd><kwd>Lasers</kwd><kwd>Neodymium</kwd><kwd>Rosacea</kwd></kwd-group><funding-group><award-group><funding-source country="KR"><institution-wrap><institution>Ministry of Health and Welfare</institution><institution-id institution-id-type="CrossRef">http://dx.doi.org/10.13039/501100003625</institution-id></institution-wrap></funding-source><award-id>HI13C2206</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Rosacea is a chronic cutaneous disease characterized by facial flushing, persistent facial redness, telangiectasia, papules and pustules. It can affect the cheeks, nose, eyes, forehead and chin<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref>. Since the face is the predominant site of involvement, rosacea has a psychosocial impact on a patient's life<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref>.</p><p>The etiopathogenesis of rosacea is not fully understood and rosacea is considered to a multifactorial disease<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref>. Factors including neuroinflammatory mechanisms, abnormalities in the congenital immune system, ultraviolet radiation, microorganisms such as <italic>Demodex folliculorum</italic> and <italic>Helicobacter pylori</italic>, dermal matrix degeneration an environmental factors, as well as changes in vessel and vascular regulation appear influential<xref rid="B3" ref-type="bibr">3</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref>.</p><p>There are numerous treatment options for rosacea, such as topical metronidazole, azelaic acid, tacrolimus, systemic antibiotics and isotretinoin. However, any treatment must be for an extended time and treatment efficacy is commonly based on anecdotal evidence<xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref>. These medications are limited in that topical and systemic agents control rosacea but do not cure it<xref rid="B13" ref-type="bibr">13</xref>.</p><p>The most effective laser for treatment of facial telangiectasia and erythema is the pulsed dye laser (PDL). It has been used to treat vascular lesions for decades. Diffuse redness can be treated with nonpurpuragenic parameter, which is very tolerable to patients<xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">15</xref><xref rid="B16" ref-type="bibr">16</xref>. Recently, various laser devices have become available to treat rosacea. But their comparative effectiveness is not clear. The 755-nm long-pulse Alexandrite laser has proven effective to treat vascular diseases refractory to PDL because of the relatively short penetration depth of PDL (about 1.2 mm). The Alexandrite laser can penetrate 50%~75% deeper into the skin than the PDL<xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr">18</xref><xref rid="B19" ref-type="bibr">19</xref><xref rid="B20" ref-type="bibr">20</xref>. Microsecond neodymium: yttrium-aluminum-garnet (Nd:YAG) laser is less painful and less risky than traditional millisecond Nd:YAG laser devices, and is effective for cutaneous vascular lesions<xref rid="B15" ref-type="bibr">15</xref><xref rid="B21" ref-type="bibr">21</xref>.</p><p>We used the dual wavelength long-pulsed 755-nm alexandrite/microsecond 1,064-nm Nd:YAG laser (LPAN) to improve treatment efficacy, taking advantage of the synergy between alexandrite and Nd:YAG laser. The aim of this study is to compare the effectiveness of the LPAN with that of 585-nm PDL for rosacea.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Trial design</title><p>This was a randomized, single-blinded, comparative study conducted at a single academic institution with a 1:1 allocation ratio. This study was approved by the Institutional Review Board at Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea (IRB no. KBSMC 2013-01-200). All patients provided written informed consent. This study was conducted in accordance with the CONSORT statement<xref rid="B22" ref-type="bibr">22</xref>.</p></sec><sec><title>Subject selection</title><p>Eligible subjects were &#x02265;18 years of age with Fitzpatrick skin types III-V, and a clinical diagnosis of rosacea with erythematotelangiectatic or papulopustular subtype. All patients underwent baseline laboratory examination with serum complete blood count, total calcium, phosphorus, fasting glucose, total protein, albumin, globulin, total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransaminase, blood urea nitrogen, creatinine, uric acid, total cholesterol and urinalysis.</p><p>Study exclusion criteria included severe phymatous or ocular rosacea, any other concurrent skin condition affecting the face, history of keloid, history of photosensitive disease, treatment with oral isotretinoin during the 6 months prior to the study, any oral medication or treatment that could affect facial erythema during the month prior to the study, history of alcohol abuse, and pregnant or lactating women.</p></sec><sec><title>Randomization</title><p>Randomization was achieved by determining the treatment laser for each subject number before assigning any subject with a subject number. Each subject was treated with the same laser every month for four consecutive treatments.</p></sec><sec><title>Intervention</title><p>After informed consent was obtained, the subjects were randomly assigned to treatment with LPAN or PDL in form of a person-by-person comparison. Before the treatment, all makeup was removed and each subject's face was cleansed with a mild soap. Half of the total subjects were treated with the dual wavelength long-pulsed 755-nm alexandrite/microsecond 1,064-nm Nd:YAG laser (Clarity&#x000ae;; Lutronic Inc., Seoul, Korea) using fluence 30 J/cm<sup>2</sup> with a spot size of 10 mm and pulse width of 12 ms for the alexandrite laser and fluence 3.0 J/cm<sup>2</sup> with a spot size of 10 mm and pulse width of 0.5 ms for Nd:YAG laser. The others were treated with the 585-nm, long-pulsed PDL (Cynergy&#x000ae;; Cynosure Inc., Westford, MA, USA) using fluence 7 J/cm<sup>2</sup> with a spot size of 10 mm and pulse width of 6 ms for PDL. The entire area of the face was treated with two passes with at least 15% overlap for the Alexandrite and PDL lasers, and with six passes for the microsecond 1,064-nm Nd:YAG laser. Each subject received the treatment by a single operator using an identical technique.</p></sec><sec><title>Primary outcome</title><p>The primary outcome was the mean reduction of the erythema index measured by a spectrophotometer from baseline to 2-weeks and 6-months after the completion of the treatment protocol. A Dermatospectrometer spectrophotometer (Cortex Technology Inc., Hadsund, Denmark) was used to quantify erythema. Three measurements on a total of seven sites (two sites on each side of the cheek: upper cheek [malar area, 2 cm below midpupillary line] and lower cheek [6 cm below midpupillary line], and three sites on the nose: nasal tip and each side of nasal ala) were performed at baseline and at each follow-up visit, and the mean value of the measurements was used as the erythema index in the analysis.</p></sec><sec><title>Secondary outcomes</title><p>The secondary outcomes included: (1) the proportion of physician's global assessment and (2) subjective satisfaction assessment; the procedure-associated (3) pain scores and (4) adverse effects. Color digital photographs of the full face were taken under the fixed position and same conditions (light source, room, and camera) using a Dermavision digital imaging system (Optobiomed Inc., Gangwon, Korea) at baseline, and 2 weeks and 6 months after the last treatment. The physician's global assessment was evaluated by two blinded consultant dermatologists based on the cross parallel image between baseline and 2 weeks after the last treatment photographs, and the cross parallel image between baseline and 6 months after the last treatment photographs using the following grading system: 1=worsening, 2=no change, 3=improved (&#x0003c;50%), and 4=much improved (50%~100%). All patients completed a questionnaire that assessed their subjective satisfaction of treatment using the following grading system: 1=no change or worsening, 2=poor, 3=fair, 4=good, and 5=excellent 6 months after the last treatment. The procedure-associated pain scores after each treatment were assessed using a 10-point visual analogue scale, and any procedure-associated adverse effects, such as erythema, cursts, pigmentary change, vesicles, dryness, itching, tightening sense and scar, during the study were recorded.</p></sec><sec><title>Statistical methods</title><p>Continuous variables were expressed as mean with standard deviations. The &#x003c7;<sup>2</sup> test was used to determine whether there was significant difference in variables expressed by frequency or proportion between subjects receiving LPAN and PDL. The independent t-test was performed to examine differences in continuous variables between subjects receiving LPAN and PDL treatment. The paired t-test was performed to compare the erythema index between baseline, 2 weeks and 6 months after the last treatment. All analyses were performed using the IBM SPSS Statistics ver. 22.0 software (IBM Co., Armonk, NY, USA). Statistical significance was considered when <italic>p</italic>-value was &#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Progression of the subjects throughout the study is presented in <xref ref-type="fig" rid="F1">Fig. 1</xref>. After evaluating 54 subjects for inclusion, 49 subjects with rosacea were enrolled. Twelve subsequently dropped out. Eleven were lost before last follow-up and one subject treated with the PDL dropped out reporting post-treatment worsening. Thirty seven subjects completed the trial; they were Fitzpatrick skin phototypes III (n=2), IV (n=30) and V (n=5). Baseline demographics and clinical characteristics of subjects are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. At baseline, there were no differences in demographics and clinical characteristics between the subjects treated with the LPAN and PDL.</p><p>Erythema index measured by spectrophotometer was significantly reduced at 2 weeks after four treatments for both LPAN and PDL, with a mean difference of 7.9% (<italic>p</italic>&#x0003c;0.001; 95% confidence interval [CI], -11.4 to -4.34) and 5.3% (<italic>p</italic>&#x0003c;0.001; 95% CI, -8.44 to -2.09), respectively. Six months after the last treatments (last follow-up), the reduction of erythema index was maintained, with a mean difference of 3.6% (<italic>p</italic>=0.035; 95% CI, -6.93 to -2.82) for LPAN and 2.8% (<italic>p</italic>=0.206; 95% CI, -7.31 to 1.69) for PDL (<xref ref-type="table" rid="T2">Table 2</xref>). When comparing the mean reduction of erythema index in both lasers, the mean change was comparable, and there were no statistical differences 2 weeks after the last treatments (<italic>p</italic>=0.313) and 6 months after the last treatments (<italic>p</italic>=0.812). <xref ref-type="fig" rid="F2">Fig. 2</xref> and <xref ref-type="fig" rid="F3">3</xref> are photographs of subjects at baseline, and 2 weeks and 6 months after the last treatment.</p><p>The proportion of the physician's global assessment from baseline to 2 weeks and 6 months after the treatments are presented in <xref ref-type="table" rid="T3">Table 3</xref>. Two weeks after treatments, the proportion of improved or much improved varied (<italic>p</italic>=0.025) by treatment, with PDL showing a proportion of 68.4%, compared with 50.0% for LPAN. However, the proportion of improved or much improved increased during follow-up, with no statistical differences between LPAN and PDL 6 months after the treatments (<italic>p</italic>=1.000; 88.9% vs. 89.5%).</p><p>Subject satisfaction assessments after the treatments are presented in <xref ref-type="fig" rid="F4">Fig. 4</xref>. There was no significant difference in the proportion of good or excellent between LPAN and PDL (<italic>p</italic>=0.842; 77.8% vs. 84.2%).</p><p>The treatment-related adverse effects are summarized in <xref ref-type="table" rid="T4">Table 4</xref>. Most subjects noted mild erythema after the both laser treatments (66.7% for LPAN and 52.6% for PDL). It faded within 2 weeks. Skin tightening and itching sense were also noted in many cases. Pain scores were not significantly different (<italic>p</italic>=0.108), with LPAN at 2.44 and PDL at 3.42. Although serious or permanent adverse events were not observed, adverse effect such as vesicles (26.3%) was significantly more observed in PDL than in LPAN (<italic>p</italic>=0.046). Post-therapy hyperpigmentation was observed in one subject per each laser group.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our study compared the effectiveness of two lasers for rosacea treatment and resulted in several important findings. Firstly, both LPAN and PDL treatments reduced erythema index measured by spectrophotometry from baseline. There was no statistical difference in mean change of erythema index between both lasers. The reduced erythema index was maintained until 6 months after the final treatments. Secondly, in physician's global assessment, PDL showed high proportion of subjects with more than 50% improvement at short-term follow-up, but there was no significant difference between LPAN and PDL at long-term follow-up. Thirdly, in subject satisfaction assessment, both lasers were similarly rated. Fourthly, the adverse effects of erythema were frequent but well tolerated in both treatment groups. Subjects receiving PDL showed more significant adverse effect such as vesicles than those receiving LPAN. Lastly, serious or permanent adverse events were not observed in both treatment groups. Collectively, our results suggest that both the LPAN and PDL can be effective and safe modalities for the treatment of rosacea and facial erythema.</p><p>Deeper penetration by the longer wavelength of the LPAN is possible explanation for its effectiveness. With the longer wavelength of 755-nm and 1,064-nm lasers can penetrate greater depth and deeper tissues can be targeted. Also, longer wavelength laser beams are able to penetrate dilated capillary walls more effectively.<xref rid="B19" ref-type="bibr">19</xref> The latter study compared the long-pulsed PDL and long-pulsed Alexandrite laser in patients with port wine stain; both laser devices effectively reduced the erythema index as measured by erythema reflectance spectrometry. Say et al.<xref rid="B23" ref-type="bibr">23</xref> reported that long-pulsed Nd:YAG is a safe and effective modality for vascular and inflammatory lesions of rosacea with high fluence of 100 to 160 J/cm<sup>2</sup>, 15 to 20 ms pulse width and 2 to 3 mm spot size. In a double-blind randomized controlled trial comparing microsecond Nd:YAG laser and nonpurpuragenic PDL for treatment of diffuse facial erythema, PDL showed a better effect than microsecond Nd:YAG, but microsecond Nd:YAG laser produced less pain than PDL.<xref rid="B15" ref-type="bibr">15</xref> In another study with hidradenitis suppurativa patients, through ablation of hair follicles and selective photothermolysis, long-pulsed Nd:YAG was an effective modality for inflammatory lesions.<xref rid="B24" ref-type="bibr">24</xref> It seems that Alexandrite and PDL have synergistic effect on treatment of rosacea. This remains to be conclusively verified.</p><p>This study adds to the existing literature on treatment of rosacea and facial erythema with laser. In our study, all subjects with rosacea ceased the any medication such as minocycline, doxycycline, isotretinoin, topical tacrolimus, or topical metronidazole at least 1 month prior to the study (for isotretinoin, at least 6 months prior to the study). However, in about half of all subjects, therapeutic effects were maintained for 6 months after the laser treatments without any medication. To our knowledge, this study is the first using LPAN laser for rosacea comparing to traditional nonpurpuragenic PDL.</p><p>In this study, the reduction of erythema index was well maintained at the long term follow-up. Interestingly, the physician's global assessment of long term follow-up seemed to be better compared to that of short term. The latter was evaluated at two weeks after the last treatment and that period was thought to be an acute phase of post laser irradiation, which occurring healing and remodeling process of target tissue. Thus the physician's global assessment at the short term follow-up may be due to transient redness which is laser induced flushing or microvascular purpura.</p><p>Concerning adverse effects, Alam et al.<xref rid="B15" ref-type="bibr">15</xref> reported that Nd:YAG laser had a lower risk of unintentional bruising than PDL, and PDL showed purpuric macules during laser treatment. In other studies using microsecond Nd:YAG settings, pain and adverse effects were less than traditional millisecond settings.<xref rid="B15" ref-type="bibr">15</xref><xref rid="B21" ref-type="bibr">21</xref> Although a non-purpuragenic parameter was used in this study, subjects receiving PDL showed more significant complications, such as vesicles, than those receiving LPAN. In light of this finding, LPAN seems to be a safer treatment than PDL in treatment of rosacea.</p><p>There are several limitations in the general application of the study findings. Firstly, as with all studies comparing two devices, there is no way to be absolutely certain that the settings were comparable, since those have different parameters and laser settings. Secondly, because the spectrophotometer measured only small spots, erythema index might not reflect the entire severity of rosacea or facial erythema. Thirdly, in subjects receiving LPAN treatments, it is difficult to determine the effect of each laser separately. Fourthly, all the subjects were of Korean with darker skin types, which may limit the generalizability of the study.</p><p>In conclusion, this study demonstrates that both the LPAN and PDL are very effective and tolerable treatments for rosacea. The LPAN treatment may be an alternative modality for rosacea when conventional PDL devices cannot be used. Future studies with split-face comparison, various laser settings, and comparison of long-pulsed alexandrite and PDL are necessary to establish the optimal treatment devices and settings for rosacea treatment.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>This research was supported by a grant of the Korea Health Technology R&#x00026;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &#x00026; Welfare, Republic of Korea (grant number : HI13C2206).</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erceg</surname><given-names>A</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>The efficacy of pulsed dye laser treatment for inflammatory skin diseases: a systematic review</article-title><source>J Am Acad Dermatol</source><year>2013</year><volume>69</volume><fpage>609</fpage><lpage>615.e8</lpage><pub-id pub-id-type="pmid">23711766</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>FC</given-names></name></person-group><article-title>Clinical practice. Rosacea</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>793</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">15728812</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>GH</given-names></name><name><surname>Pelle</surname><given-names>MT</given-names></name><name><surname>James</surname><given-names>WD</given-names></name></person-group><article-title>Rosacea: I. Etiology, pathogenesis, and subtype classification</article-title><source>J Am Acad Dermatol</source><year>2004</year><volume>51</volume><fpage>327</fpage><lpage>341</lpage><comment>quiz 342-324</comment><pub-id pub-id-type="pmid">15337973</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksoy</surname><given-names>B</given-names></name><name><surname>Altaykan-Hapa</surname><given-names>A</given-names></name><name><surname>Egemen</surname><given-names>D</given-names></name><name><surname>Karag&#x000f6;z</surname><given-names>F</given-names></name><name><surname>Atakan</surname><given-names>N</given-names></name></person-group><article-title>The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities</article-title><source>Br J Dermatol</source><year>2010</year><volume>163</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">20545683</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>T</given-names></name></person-group><article-title>Clinical presentations and classification of rosacea</article-title><source>Ann Dermatol Venereol</source><year>2011</year><volume>138</volume><issue>Suppl 3</issue><fpage>S192</fpage><lpage>S200</lpage><pub-id pub-id-type="pmid">22183098</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>K</given-names></name><name><surname>Gallo</surname><given-names>RL</given-names></name></person-group><article-title>The molecular pathology of rosacea</article-title><source>J Dermatol Sci</source><year>2009</year><volume>55</volume><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">19481425</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinholz</surname><given-names>M</given-names></name><name><surname>Tietze</surname><given-names>JK</given-names></name><name><surname>Kilian</surname><given-names>K</given-names></name><name><surname>Schaller</surname><given-names>M</given-names></name><name><surname>Sch&#x000f6;fer</surname><given-names>H</given-names></name><name><surname>Lehmann</surname><given-names>P</given-names></name><etal/></person-group><article-title>Rosacea-S1 guideline</article-title><source>J Dtsch Dermatol Ges</source><year>2013</year><volume>11</volume><fpage>768</fpage><lpage>780</lpage><fpage>768</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">23647643</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cribier</surname><given-names>B</given-names></name></person-group><article-title>Pathophysiology of rosacea: redness, telangiectasia, and rosacea</article-title><source>Ann Dermatol Venereol</source><year>2011</year><volume>138</volume><issue>Suppl 3</issue><fpage>S184</fpage><lpage>S191</lpage><pub-id pub-id-type="pmid">22183097</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>VD</given-names></name><name><surname>Sulk</surname><given-names>M</given-names></name><name><surname>Seeliger</surname><given-names>S</given-names></name><name><surname>Nowak</surname><given-names>P</given-names></name><name><surname>Aubert</surname><given-names>J</given-names></name><name><surname>Mess</surname><given-names>C</given-names></name><etal/></person-group><article-title>Neurovascular and neuroimmune aspects in the pathophysiology of rosacea</article-title><source>J Investig Dermatol Symp Proc</source><year>2011</year><volume>15</volume><fpage>53</fpage><lpage>62</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zuuren</surname><given-names>EJ</given-names></name><name><surname>Kramer</surname><given-names>SF</given-names></name><name><surname>Carter</surname><given-names>BR</given-names></name><name><surname>Graber</surname><given-names>MA</given-names></name><name><surname>Fedorowicz</surname><given-names>Z</given-names></name></person-group><article-title>Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review</article-title><source>Br J Dermatol</source><year>2011</year><volume>165</volume><fpage>760</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">21692773</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelle</surname><given-names>MT</given-names></name><name><surname>Crawford</surname><given-names>GH</given-names></name><name><surname>James</surname><given-names>WD</given-names></name></person-group><article-title>Rosacea: II. Therapy</article-title><source>J Am Acad Dermatol</source><year>2004</year><volume>51</volume><fpage>499</fpage><lpage>512</lpage><comment>quiz 513-514</comment><pub-id pub-id-type="pmid">15389184</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elewski</surname><given-names>BE</given-names></name><name><surname>Draelos</surname><given-names>Z</given-names></name><name><surname>Dr&#x000e9;no</surname><given-names>B</given-names></name><name><surname>Jansen</surname><given-names>T</given-names></name><name><surname>Layton</surname><given-names>A</given-names></name><name><surname>Picardo</surname><given-names>M</given-names></name></person-group><article-title>Rosacea-global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group</article-title><source>J Eur Acad Dermatol Venereol</source><year>2011</year><volume>25</volume><fpage>188</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">20586834</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>HE</given-names></name></person-group><article-title>Systemic therapy for rosacea</article-title><source>Skin Ther Lett</source><year>2007</year><volume>12</volume><fpage>1</fpage><lpage>5</lpage><fpage>9</fpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>KA</given-names></name><name><surname>Garden</surname><given-names>JM</given-names></name></person-group><article-title>The pulsed dye laser for cutaneous vascular and nonvascular lesions</article-title><source>Semin Cutan Med Surg</source><year>2000</year><volume>19</volume><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">11149608</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>M</given-names></name><name><surname>Voravutinon</surname><given-names>N</given-names></name><name><surname>Warycha</surname><given-names>M</given-names></name><name><surname>Whiting</surname><given-names>D</given-names></name><name><surname>Nodzenski</surname><given-names>M</given-names></name><name><surname>Yoo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Comparative effectiveness of non-purpuragenic 595-nm pulsed dye laser and microsecond 1064-nm neodymium:yttrium-aluminum-garnet laser for treatment of diffuse facial erythema: a double-blind randomized controlled trial</article-title><source>J Am Acad Dermatol</source><year>2013</year><volume>69</volume><fpage>438</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">23688651</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jasim</surname><given-names>ZF</given-names></name><name><surname>Woo</surname><given-names>WK</given-names></name><name><surname>Handley</surname><given-names>JM</given-names></name></person-group><article-title>Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold</article-title><source>Dermatol Surg</source><year>2004</year><volume>30</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">14692924</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zide</surname><given-names>BM</given-names></name><name><surname>Levine</surname><given-names>SM</given-names></name></person-group><article-title>Hemangioma update: pearls from 30 years of treatment</article-title><source>Ann Plast Surg</source><year>2012</year><volume>69</volume><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">21734553</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kauvar</surname><given-names>AN</given-names></name><name><surname>Lou</surname><given-names>WW</given-names></name></person-group><article-title>Pulsed alexandrite laser for the treatment of leg telangiectasia and reticular veins</article-title><source>Arch Dermatol</source><year>2000</year><volume>136</volume><fpage>1371</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">11074700</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Kono</surname><given-names>T</given-names></name><name><surname>Groff</surname><given-names>WF</given-names></name><name><surname>Chan</surname><given-names>HH</given-names></name><name><surname>Kitazawa</surname><given-names>Y</given-names></name><name><surname>Nozaki</surname><given-names>M</given-names></name></person-group><article-title>Comparison study of a long-pulse pulsed dye laser and a long-pulse pulsed alexandrite laser in the treatment of port wine stains</article-title><source>J Cosmet Laser Ther</source><year>2008</year><volume>10</volume><fpage>12</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">18330793</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Ke</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name></person-group><article-title>Beneficial effects of early treatment of infantile hemangiomas with a long-pulse Alexandrite laser</article-title><source>Lasers Surg Med</source><year>2014</year><volume>46</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">24391080</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahcan</surname><given-names>U</given-names></name><name><surname>Zorman</surname><given-names>P</given-names></name><name><surname>Recek</surname><given-names>D</given-names></name><name><surname>Ralca</surname><given-names>S</given-names></name><name><surname>Majaron</surname><given-names>B</given-names></name></person-group><article-title>Port wine stain treatment with a dual-wavelength Nd:Yag laser and cryogen spray cooling: a pilot study</article-title><source>Lasers Surg Med</source><year>2004</year><volume>34</volume><fpage>164</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">15004829</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group><collab>CONSORT Group</collab><article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials</article-title><source>Open Med</source><year>2010</year><volume>4</volume><fpage>e60</fpage><lpage>e68</lpage><pub-id pub-id-type="pmid">21686296</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Say</surname><given-names>EM</given-names></name><name><surname>Okan</surname><given-names>G</given-names></name><name><surname>G&#x000f6;kdemir</surname><given-names>G</given-names></name></person-group><article-title>Treatment outcomes of long-pulsed Nd: YAG laser for two different subtypes of rosacea</article-title><source>J Clin Aesthet Dermatol</source><year>2015</year><volume>8</volume><fpage>16</fpage><lpage>20</lpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tard&#x000ed;o</surname><given-names>JC</given-names></name><name><surname>Pinedo</surname><given-names>F</given-names></name><name><surname>Aramburu</surname><given-names>JA</given-names></name><name><surname>Su&#x000e1;rez-Massa</surname><given-names>D</given-names></name><name><surname>Pamp&#x000ed;n</surname><given-names>A</given-names></name><name><surname>Requena</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated</article-title><source>J Cutan Pathol</source><year>2016</year><volume>43</volume><fpage>101</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">26264237</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Flow diagram according to CONSORT guidelines showing the flow of subjects in the trial. PDL: 585-nm pulsed dye laser, LPAN: dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium: yttrium-aluminum-garnet laser.</title></caption><graphic xlink:href="ad-28-607-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><title>(A~C) Male patient. (A) Before treatment, (B) at 2 weeks after four 585-nm pulsed dye laser (PDL) treatments, (C) at 6 months after last treatment. (D~F) Female patient. (D) Before treatment, (E) after four PDL treatments, (F) at 6-month after final treatment.</title></caption><graphic xlink:href="ad-28-607-g002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><title>(A~C) Male patient. (A) Before treatment, (B) at 2 weeks after four dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium:yttrium-aluminum-garnet laser (LPAN) treatments, (C) at 6 months after last treatment. (D~F) Female patient. (D) Before treatment, (E) after four LPAN treatments, (F) at 6 months after final treatment.</title></caption><graphic xlink:href="ad-28-607-g003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Fig. 4</label><caption><title>Subjective satisfaction assessment for the treatments. <sup>*</sup>No significant difference in the proportion of good or excellent between both treatments (<italic>p</italic>=0.842). PDL: 585-nm pulsed dye laser, LPAN: dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium:yttrium-aluminum-garnet laser.</title></caption><graphic xlink:href="ad-28-607-g004"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Demographics and clinical characteristics of the study subjects</title></caption><alternatives><graphic xlink:href="ad-28-607-i001"/><table frame="hsides" rules="rows"><col width="35.71%" span="1"/><col width="24.07%" span="1"/><col width="24.07%" span="1"/><col width="16.14%" span="1"/><thead><tr><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">Characteristic</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">PDL (n=19)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">LPAN (n=18)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)"><italic>p</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (yr)</td><td valign="top" align="center" rowspan="1" colspan="1">48.6&#x000b1;11.3</td><td valign="top" align="center" rowspan="1" colspan="1">49.9&#x000b1;12.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.733</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">11 (57.9)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (44.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.413</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rosacea duration (yr)</td><td valign="top" align="center" rowspan="1" colspan="1">11.0&#x000b1;15.4</td><td valign="top" align="center" rowspan="1" colspan="1">7.5&#x000b1;9.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.416</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rosacea severity</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="4" colspan="1">0.384</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Mild</td><td valign="top" align="center" rowspan="1" colspan="1">11 (57.9)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (77.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">4 (21.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (16.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Severe</td><td valign="top" align="center" rowspan="1" colspan="1">4 (21.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (5.6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline erythema index</td><td valign="top" align="center" rowspan="1" colspan="1">18.1&#x000b1;3.8</td><td valign="top" align="center" rowspan="1" colspan="1">17.3&#x000b1;2.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.433</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation or number (%). PDL: 585-nm pulsed dye laser, LPAN: dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium:yttrium-aluminum-garnet laser.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Erythema index results with pairwise comparisons between time periods</title></caption><alternatives><graphic xlink:href="ad-28-607-i002"/><table frame="hsides" rules="rows"><col width="11.84%" span="1"/><col width="11.84%" span="1"/><col width="11.84%" span="1"/><col width="11.84%" span="1"/><col width="14.89%" span="1"/><col width="11.84%" span="1"/><col width="14.04%" span="1"/><col width="11.84%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="2" colspan="1" style="background-color:rgb(192,192,192)"/><th valign="middle" align="center" rowspan="2" colspan="1" style="background-color:rgb(192,192,192)">Before treatment</th><th valign="middle" align="center" rowspan="2" colspan="1" style="background-color:rgb(192,192,192)">Short-term follow-up</th><th valign="middle" align="center" rowspan="2" colspan="1" style="background-color:rgb(192,192,192)">Long-term follow-up</th><th valign="middle" align="center" rowspan="1" colspan="2" style="background-color:rgb(192,192,192)">Between baseline and short-term follow-up</th><th valign="middle" align="center" rowspan="1" colspan="2" style="background-color:rgb(192,192,192)">Between baseline and long-term follow-up</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">Difference in means</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)"><italic>p</italic>-value</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">Difference in means</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)"><italic>p</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">LPAN</td><td valign="top" align="center" rowspan="1" colspan="1">17.3&#x000b1;2.3</td><td valign="top" align="center" rowspan="1" colspan="1">16.0&#x000b1;2.6</td><td valign="top" align="center" rowspan="1" colspan="1">16.7&#x000b1;2.4</td><td valign="top" align="center" rowspan="1" colspan="1">1.36&#x000b1;1.23</td><td valign="top" align="right" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">0.63&#x000b1;1.16</td><td valign="top" align="center" rowspan="1" colspan="1">0.035</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PDL</td><td valign="top" align="center" rowspan="1" colspan="1">18.1&#x000b1;3.8</td><td valign="top" align="center" rowspan="1" colspan="1">17.2&#x000b1;4.2</td><td valign="top" align="center" rowspan="1" colspan="1">17.6&#x000b1;3.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.96&#x000b1;1.20</td><td valign="top" align="right" rowspan="1" colspan="1">0.003</td><td valign="top" align="center" rowspan="1" colspan="1">0.51&#x000b1;1.70</td><td valign="top" align="center" rowspan="1" colspan="1">0.206</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation. LPAN: dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium: yttrium-aluminum-garnet laser, PDL: 585-nm pulsed dye laser. Short-term follow up: 2-week after the last treatment, long-term follow up: 6-month after the last treatment.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Proportion of the physician's global assessment</title></caption><alternatives><graphic xlink:href="ad-28-607-i003"/><table frame="hsides" rules="rows"><col width="21.8%" span="1"/><col width="19.55%" span="1"/><col width="19.55%" span="1"/><col width="19.55%" span="1"/><col width="19.55%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="2" colspan="1" style="background-color:rgb(192,192,192)">Physician&#x02019;s global assessment</th><th valign="middle" align="center" rowspan="1" colspan="2" style="background-color:rgb(192,192,192)">LPAN (n=18)</th><th valign="middle" align="center" rowspan="1" colspan="2" style="background-color:rgb(192,192,192)">PDL (n=19)</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">Short-term follow-up</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">Long-term follow-up</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">Short-term follow-up</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">Long-term follow-up</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Worse</td><td valign="top" align="center" rowspan="1" colspan="1">3 (16.7)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (31.6)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (10.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No change</td><td valign="top" align="center" rowspan="1" colspan="1">6 (33.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Improved</td><td valign="top" align="center" rowspan="1" colspan="1">7 (38.9)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (44.4)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (47.4)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (36.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Much improved</td><td valign="top" align="center" rowspan="1" colspan="1">2 (11.1)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (44.4)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (21.1)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (52.6)</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are presented as number (%). LPAN: dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium: yttrium-aluminum-garnet laser, PDL: 585-nm pulsed dye laser. Short-term follow up: 2-week after the last treatment, long-term follow up: 6-month after the last treatment.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Adverse effects</title></caption><alternatives><graphic xlink:href="ad-28-607-i004"/><table frame="hsides" rules="rows"><col width="37.37%" span="1"/><col width="22.9%" span="1"/><col width="22.9%" span="1"/><col width="16.84%" span="1"/><thead><tr><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">Adverse effect</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">LPAN</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)">PDL</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(192,192,192)"><italic>p</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Erythema</td><td valign="top" align="center" rowspan="1" colspan="1">12 (66.7)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (52.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.385</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crusts</td><td valign="top" align="center" rowspan="1" colspan="1">2 (11.1)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (31.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.232</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hyperpigmentation</td><td valign="top" align="center" rowspan="1" colspan="1">1 (5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vesicles</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (26.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.046</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dryness</td><td valign="top" align="center" rowspan="1" colspan="1">4 (22.2)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (15.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Itching sense</td><td valign="top" align="center" rowspan="1" colspan="1">6 (33.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (15.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.269</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tightening sense</td><td valign="top" align="center" rowspan="1" colspan="1">4 (22.2)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (31.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.714</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are presented as number (%). LPAN: dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium:yttrium-aluminum-garnet laser, PDL: 585-nm pulsed dye laser.</p></fn></table-wrap-foot></table-wrap></floats-group></article>